Abstract
INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.
| Original language | English |
|---|---|
| Journal | Expert Review of Anti-Infective Therapy |
| DOIs | |
| Publication status | E-pub ahead of print - Dec 24 2018 |
Fingerprint
Cite this
Real life experiences in HCV management in 2018. / Viganò, Mauro; Andreoni, Massimo; Perno, Carlo Federico; Craxì, Antonio; Aghemo, Alessio; Alberti, Alfredo; Andreone, Pietro; Babudieri, Sergio; Bonora, Stefano; Brunetto, Maurizia Rossana; Bruno, Raffaele; Bruno, Savino; Calvaruso, Vincenza; Caporaso, Nicola; Cartabellotta, Fabio; Ceccherini-Silberstein, Francesca; Cento, Valeria; Ciancio, Alessia; Colombatto, Piero; Coppola, Nicola; Di Marco, Vito; Di Perri, Giovanni; Fagiuoli, Stefano; Gaeta, Giovanni Battista; Gasbarrini, Antonio; Lampertico, Pietro; Pellicelli, Adriano; Prestileo, Tullio; Puoti, M; Raimondo, G; Rizzardini, Giuliano; Taliani, Gloria; Zignego, Anna Linda.
In: Expert Review of Anti-Infective Therapy, 24.12.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Real life experiences in HCV management in 2018
AU - Viganò, Mauro
AU - Andreoni, Massimo
AU - Perno, Carlo Federico
AU - Craxì, Antonio
AU - Aghemo, Alessio
AU - Alberti, Alfredo
AU - Andreone, Pietro
AU - Babudieri, Sergio
AU - Bonora, Stefano
AU - Brunetto, Maurizia Rossana
AU - Bruno, Raffaele
AU - Bruno, Savino
AU - Calvaruso, Vincenza
AU - Caporaso, Nicola
AU - Cartabellotta, Fabio
AU - Ceccherini-Silberstein, Francesca
AU - Cento, Valeria
AU - Ciancio, Alessia
AU - Colombatto, Piero
AU - Coppola, Nicola
AU - Di Marco, Vito
AU - Di Perri, Giovanni
AU - Fagiuoli, Stefano
AU - Gaeta, Giovanni Battista
AU - Gasbarrini, Antonio
AU - Lampertico, Pietro
AU - Pellicelli, Adriano
AU - Prestileo, Tullio
AU - Puoti, M
AU - Raimondo, G
AU - Rizzardini, Giuliano
AU - Taliani, Gloria
AU - Zignego, Anna Linda
PY - 2018/12/24
Y1 - 2018/12/24
N2 - INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.
AB - INTRODUCTION: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient's identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.
U2 - 10.1080/14787210.2019.1563755
DO - 10.1080/14787210.2019.1563755
M3 - Article
C2 - 30582384
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
SN - 1478-7210
ER -